Latest News for: hoth

Edit

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

PR Newswire 02 Apr 2025
NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc ... HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St ... About Hoth Therapeutics, Inc.
Edit

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

PR Newswire 02 Apr 2025
NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc ... "Our findings highlight a powerful new therapeutic approach for Alzheimer's by targeting astrocyte-driven neuroinflammation," said Robb Knie, CEO of Hoth Therapeutics.
Edit

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) (Hoth Therapeutics Inc)

Public Technologies 28 Mar 2025
). MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS ... Our actual results may differ materially from those discussed below ... All amounts in this report are in U.S. dollars, unless otherwise noted ... Hoth Therapeutics Inc.
Edit

Material Agreement, Non-Reliance of Financial Report (Form 8-K) (Hoth Therapeutics Inc)

Public Technologies 25 Mar 2025
) ... On March 24, 2024, Hoth Therapeutics, Inc. ("Hoth" or the "Company") entered into a Project Order Agreement (the "Agreement") with OnTargetx R&D Inc ... 701821 (P210614002-B) ... Disclaimer. Hoth Therapeutics Inc ... (noodl.
Edit

Thompson, Lila (Hoth)

HJ News 22 Mar 2025
Thompson Lila Hoth Thompson 87 Logan passed away March 20, 2025. Memories and condolences may be shared and expressed at www.allenmortuaries.com ....
Edit

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

PR Newswire 18 Mar 2025
NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc ... "These exciting findings mark a significant milestone in the development of HT-KIT as a potential new therapeutic for patients with GIST," said Robb Knie, CEO of Hoth Therapeutics.
  • 1
×